Basal cell carcinoma (BCC) is the most common skin tumor in Caucasians. Loss of heterozygosity (LOH) of chromosome 9 (9q22.3) is common in BCCs, and indirectly implies their monoclonal origin. Although BCCs are considered monoclonal tumors, the clonal origin of anatomically distinct tumors in the same patient was rarely investigated. Forty-one anatomically distinct BCCs from 15 female patients were genotyped for LOH at chromosome 9q22.3, and the inactivation pattern of X-chromosome using the androgen receptor polymorphic site. Overall, 11 women with 30 tumors were heterozygous (informative) with either one of the two 9q markers or the androgen receptor polymorphism. LOH of 9q was detected in 20 tumors from seven patients, and in all tumors derived from the same patient, the same allele was lost. An identical X-chromosome inactivation pattern was noted in all four tumors taken from one patient, and in another informative patient, one tumor demonstrated LOH and the other retained it. In five tumors from two patients, there was no evidence of monoclonality using either technique. We conclude that the majority of anatomically distinct BCCs are monoclonal neoplasms and may represent expansion of the same clone. Abbreviations: BCC, basal cell carcinoma; LOH, loss of heterozygosity Vogelstein B, Fearon ER, Hamilton SR, Preisinger AC, Willard HF, Michelson AM et al. (1987) Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res 47:4806-13 Walsh DC, Peacocke M, Harrington A, James WD, Tsou HC (1998) Patterns of X chromosome inactivation in sporadic basal cell carcinoma: evidence for monoclonality. J Am Acad Dermatol 38:49-55 Walsh DS, Tsou HC, Harrington A, James WD, Peacocke M (1996) Clonality of basal cell carcinoma-molecular analysis of an interesting case. J Invest Dermatol 106:579-82 www.jidonline.org 679 O Shulman et al.
INTRODUCTION
Basal cell carcinoma (BCC), the most common skin tumor in Caucasians, originates from the basal layer of the epithelium or from the external root sheath of the hair follicle (Aston et al., 1997) . It is a slow growing tumor characterized by direct or perineural invasion, and it almost never metastasizes (Aston et al., 1997) . BCC is associated with multiple risk factors: UV and ionizing radiation, immunologic factors, chemical exposure, skin type, and rare genetic syndromes, for example, xeroderma pigmentosum, albinism, and Gorlin syndrome (Aston et al., 1997) . The gene for Gorlin syndrome is located on the long arm of chromosome 9 (Gailani et al., 1992; Jin et al., 1997; Unden et al., 1997) , a region that frequently displays allelic loss (loss of heterozygosity -LOH) in both sporadic and Gorlin syndrome-associated BCC (Gailani et al., 1992; Quinn et al., 1994; Unden et al., 1997; He et al., 1999; Shen et al., 1999; Saridaki et al., 2000) . LOH is taken as indirect evidence for the clonal origin of a tumor (Saldanha et al., 2002; Iwata et al., 2004) . The ''gold standard'' for determining the monoclonal origin of a tumor is determination of the pattern of X-chromosome inactivation, using either enzymatic (Linder and Gartler, 1965) or DNA-based assays (Fialkow et al., 1980; Gale and Linch, 1998) : in a monoclonal tumor, the same X-chromosome (either maternal or paternal) is inactivated in every cell of the tumor, whereas in polyclonal tissues, the X-chromosome inactivation occurs randomly and affects either the maternal-or paternal-derived X-chromosome (Vogelstein et al., 1987; Allen et al., 1992) .
The clonal origin of BCC has previously been studied in a limited number of patients (Walsh et al., 1996) and tumors (Walsh et al., 1998; Saldanha et al., 2002) , with demonstration of monoclonal origin in the majority of tumors. However, there are only a limited number of studies addressing the clonal origin of multiple tumors from a single individual. Walsh et al. (1996) demonstrated a single clone of cells with nonrandom X-chromosome inactivation pattern in five BCCs taken from the face of one female patient. Saldanha and co-workers (2002) , analyzing separate nests of superficial BCC, detected LOH of the same 9q allele in distinct nests in 2/6 BCCs, and calculated that given the identical LOH pattern, the likelihood that these nests evolved independently are statistically negligible. Walsh et al. (1998) analyzed 25 BCCs from 24 female patients, and 15 of these 25 tumors displayed a nonrandom X-inactivation pattern, consistent of monoclonal origin, whereas 10 tumors displayed no evidence of monoclonality.
In the present study, the clonal origin multiple BCC from anatomically distinct locations in the same individual was determined, by assessing 9q LOH and X-chromosome inactivation patterns. 
RESULTS

Patient characteristics and tumor features
A total of 15 women participated in the study, with a total number of 41 tumors (mean number of tumors/patient 2.73, range 2-5). Age at diagnosis and the anatomical locations of the tumors are listed in Table 1 .
LOH analysis
Four patients (nos. 1, 9, 10, and 12) with a total of 11 tumors were homozygous in the non-tumorous tissue with both 9q markers, and hence LOH was not attempted. The remaining 11 patients (with a total of 30 tumors) were heterozygous in the non-tumorous tissue using polymorphic markers on chromosome 9. Seven of these 11 patients, with a total of 20 tumors, displayed LOH by using the two 9q markers, and in all tumors from the same patient, the same allele was deleted in all anatomically distinct tumors (Figure 1 ). One patient (no. 6) retained heterozygosity of 9q in all three tumor tissues, and in another patient (no. 14), a tumor from the left cheek retained heterozygosity, and the lesion on her upper lip displayed LOH using both markers.
X-chromosome inactivation
Four patients (nos. 1, 9, 10, and 12) with a total of 11 tumors were homozygous in the non-tumorous tissue with the CAG repeat of the androgen receptor and were not suitable for analysis of X-chromosome inactivation pattern. One patient (no. 7) showed a pattern compatible with polyclonality in the two tumor tissues. One patient (no. 2), displayed Xchromosome inactivation pattern of the same X-chromosome in all four tumor tissues.
DISCUSSION
In the present study, the majority of BCC are monoclonal tumors whose tumorigenesis involves an inactivation of tumor suppressor gene(s) that localize to the long arm of chromosome 9. These data are in line with previously published studies that evaluated the clonal origin of BCC and the involvement of 9q in BCC pathogenesis (Quinn et al., 1994; Walsh et al., 1996 Walsh et al., , 1998 He et al., 1999; Shen et al., 1999; Saridaki et al., 2000; Saldanha et al., 2002; Iwata et al., 2004) . The novel aspect of this study is the finding that in anatomically distinct lesions of BCC, the same allele is lost (9q) or the same X-chromosome is inactivated. The most plausible interpretation of this finding is that these anatomically distinct lesions originate from the same parent clone. Statistically, the chances that the same allele would be lost in five distinct lesions are negligible. Previous studies performing monoclonality analysis and LOH at 9q in BCC were mostly carried out on a single lesion from a single patient (Walsh et al., 1996 (Walsh et al., , 1998 Iwata et al., 2004) . Notably, Walsh et al. (1996) demonstrated nonrandom inactivation of the same X-chromosome in five distinct BCCs from a single female patient.
In about 20% of BCC analyzed in the present study, neither technique proved that these tumors were monoclonal, and in fact at least some of these lesions may represent polyclonal tumors. In particular, two tumors from the same patient displayed an X-chromosome inactivation pattern consistent with polyclonal origin. O Shulman et al.
In one patient, the two analyzed tumors showed different patterns: LOH at 9q in one and retention of heterozygosity in the other. This finding may indicate that different molecular mechanisms underlie the pathogenesis of anatomically distinct BCC. Alternatively, the lesion that retained heterozygosity may represent a phase of polyclonal expansion that precedes actual monoclonal expansion. As this patient was non-informative for the X-chromosome inactivation patterns, this latter possibility cannot be excluded.
We conclude that the majority of BCCs are of monoclonal origin, that anatomically distinct lesions may arise from the same transformed clone, and that a small subset of BCC may in fact be polyclonal tumors.
MATERIALS AND METHODS
Patient recruitment
All female patients operated at the Department of Plastic and Reconstructive surgery, Kaplan Medical Center, Rehovot, Israel, for surgical removal of two or more anatomically distinct BCC's from 1 May 2004 were eligible for participation. In all cases, an experienced pathologist confirmed histopathological diagnosis. The Institutional Review Board approved the study, and each participant signed a written informed consent. The study was conducted according to the Declaration of Helsinki Principles.
Tumor processing
From each lesion, biopsies measuring 3 mm in diameter were taken from the superficial superior peak of the tumor and from the distal non-tumorous areas of the specimen. These tumor and non-tumor samples were collected into separate tubes until processing.
Extraction of DNA
DNA was extracted from the tumorous and non-tumorous tissues using DNEasy Tissue Kit of Qiagen company (Valencia, CA) according to the manufacturer's recommended protocol.
Genetic analyses
Determination of allelic loss (LOH) of 9q. Two polymorphic markers (D9S287, STSA002A37), both located on the long arm of chromosome 9 (at 9q22.3), were used for LOH determination. The PCR conditions and primer sequences were as described previously (Iwata et al., 2004) , and PCR products were size fractioned on an ABI 310 Prism semi-automatic sequencer (PE Biosystems, Foster City, CA), using size markers.
Inactivation patterns of the X-chromosome. This is determined by analysis of the polymorphic CAG repeat within exon 1 of the androgen receptor, using a previously published protocol (Allen et al., 1992) .
